• Blog
  • Hereditary Angioedema Market Report

    Hereditary Angioedema Market Report

    Hereditary Angioedema Market Report
    Report code - SR1529 Delivery - 2 Weeks
    Get Free Sample |
    Hereditary Angioedema Market Trends, Dynamics & Market Insights
    See more...

    Market Insights

    The Hereditary Angioedema Market is projected to grow from USD 1.9 billion in 2020 to USD 2.8 billion by 2026 at a CAGR of around 7.2% during the forecast period.

    Figure: Hereditary Angioedema Market Size, 2020-2026 (USD Billion)

    Hereditary-Angioedema-Market-Forecast

    Wish to get a free sample? Register Here

    What is hereditary angioedema?

    Hereditary angioedema is a genetic disorder characterized by persistent episodes of severe swelling (angioedema). It most commonly affects limbs, intestinal tract, face, and airway. It can be classified into three types based on genetic defects such as type I HAE with low levels of C1-INH in the body, type II with poorly functioning C1-INH, or the recently identified types of HAE with normal functioning C1-INH (formerly known as type III HAE).

    Key Players

    Key players operating in the Hereditary Angioedema market are-

    • Pharming Group NV (Netherlands)
    • Shire plc (US)
    • CSL Limited (Australia)
    • iBio Inc. (US)
    • BioCryst Pharmaceuticals, Inc. (US)
    • Ionis Pharmaceuticals (US)
    • Sanofi S.A. (France)
    • Attune Pharmaceuticals, Inc. (US)
    • Adverum Biotechnologies, Inc. (US).

    Market Dynamics

    The growth of the hereditary angioedema market is primarily driven by rising incidences of hereditary angioedema across geographies. Growing emphasis on initiatives aimed at creating awareness among consumers related to the disease is expected to augment the market growth substantially. In addition to this, increasing investment in research and development activities to develop a novel drug is likely to create lucrative opportunities for the players operating in the global hereditary angioedema market in the coming years.

    Segments' Analysis

    End-Use Trends

    By end-use, the hereditary angioedema market has been bifurcated into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment can be attributed to the convenience and availability of drugs.

    Regional Trends

    By region, the North American market accounted for the largest market share in 2020 and is projected to grow at a robust CAGR during the review period. This can be attributed to expanding geriatric populace and increasing investment in R&D activities to develop new drugs coupled with the presence of key market players such as Shire plc (US) and BioCryst Pharmaceuticals, Inc. (US). The market growth in Asia-Pacific is expected to be driven by an increasing number of people having hereditary angioedema disease.

    COVID-19 Impact on Hereditary Angioedema Market

    The covid-19 outbreak posed significant challenges across verticals worldwide. It impacted the growth of the hereditary angioedema market negatively as the diagnostic procedures other than covid-19 treatment declined due to fear of coronavirus infection. Also, supply chain disruptions due to the imposition of lockdown affected the product availability on time and thus, affected the market growth. 

    Critical Questions Answered in the Report

    • What are the key trends in the Hereditary Angioedema market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the Hereditary Angioedema market?
    • What are the key strategies adopted by the major vendors to lead in the Hereditary Angioedema market?
    • What is the market share of the top vendors?

    Get the full scope of the report. Register Here

    Target Audience

    Here is the list of the group of customers that the hereditary angioedema market hopes to have the greatest opportunity to convert-

    • Hereditary angioedema distributors
    • Hereditary angioedema suppliers
    • Hereditary angioedema manufacturers
    • Logistics organizations
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    The hereditary angioedema market is expected to witness an impressive growth of 7.2% CAGR in the coming years.

    Pharming Group NV (Netherlands), Shire plc (US), CSL Limited (Australia), iBio Inc. (US), Bio-Cryst Pharmaceuticals, Inc. (US), Ionis Pharmaceuticals (US), Sanofi S.A. (France), Attune Phar-maceuticals, Inc. (US) and Adverum Biotechnologies, Inc. (US) are among the key players in the hereditary angioedema market.

    The hereditary angioedema market size is expected to reach USD 2.8 billion in the foreseeable future.

    The hospital pharmacies segment is expected to register significant growth in the hereditary angioedema market in the coming years.

    North America accounted for the largest share in the hereditary angioedema market in 2020.

    Hereditary angioedema distributors, Hereditary angioedema suppliers, Hereditary angioedema manufacturers, Logistics organizations, Government bodies are the target audience in the hereditary angioedema market.